GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024) Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2025- GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication of its 2025 Extra-Financial Performance Report (fiscal year 2024). Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to the growing interest of institutional and individual shareholders,...
GENFIT : Publication du rapport de performance extra-financière 2025 (exercice 2024) Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 14 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la publication de son rapport de performance extra-financière 2025 (exercice 2024). Depuis 2022, GENFIT publie un rapport de performance extra-financière détaillé en réponse à l’intérêt croissant des actionnaires ins...
1Q'25 vs. 1Q'24 Results Sales: € 1.5 Bn (+4.7% vs. +3.4% BS(e) and -0.3% consensus); EBITDA: € 102 M (-8.1% vs. -1.8% BS(e) and -1.8% consensus); EBIT: € 53 M (-25.4% vs. -4.2% BS(e) and -8.5% consensus); Net Profit: € 10 M (-81.1% vs. -28.3% BS(e) and -28.3% consensus).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.